Syndax Pharmaceuticals (SNDX) PT Lowered to $26 at B.Riley/FBR

B.Riley/FBR analyst Harshita Polishetty lowered the price target on Syndax Pharmaceuticals (NASDAQ: SNDX) to $26.00 (from $40.00) while maintaining a Buy rating following 4Q report.

On the earnings call, management noted that the company has currently decided to defer the advancement of the entinostat-PD-1 combination program, which includes the previously announced ENCORE 607 registration trial in non-small cell lung cancer (NSCLC).

You May Also Be Interested In

• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2
• CAVA Group Inc (CAVA) PT Lowered to $80 at JPMorgan, Overweight Rating Maintained
• Westinghouse said to seek over $50 billion valuation in planned IPO